FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971114015> ?p ?o ?g. }

• W1971114015 endingPage "409" @default.
• W1971114015 startingPage "401" @default.
• W1971114015 abstract "Angiopoietin-1 (Ang-1) constitutes a novel family of endothelial cell-specific angiogenic factors. Ang-1 functions mainly in remodeling, maturation, and stabilization of blood vessels. Its direct role in the process of angiogenesis remains unknown. The authors designed an experimental study to investigate the angiogenic potential of Ang-1 and to determine its hemodynamic effects on the cremaster muscle flap model in the rat. Adenovirus-mediated gene therapy was used for delivery of Ang-1. The study sample included 45 male Sprague-Dawley rats weighing 200 to 250 g. After the cremaster muscle tube flaps were prepared, rats were randomized into three different groups of 15 animals. In group I (the control), the flaps received phosphate-buffered saline (PBS). In group II, flaps were treated with adenovirus vector encoding Ang-1 (Ad-Ang-1). In group III, flaps received a control gene encoding green fluorescein protein (Ad-GFP). All treatments were administered via intra-arterial injections of either viral particles (10(8) placque-forming units) or PBS. The external iliac artery was used for this purpose. The cremaster tube flap was then preserved in a subcutaneous pocket in the lower limb. The tube flap was withdrawn from the limb on days 3, 7, and 14 after intra-arterial injection to evaluate microcirculatory measurements such as red blood cell velocity, vessel diameter, capillary density, and microvascular permeability by intravital microscopy. Evaluations were performed by an investigator who was blinded to treatment groups. In a series of control experiments performed with Ad-GFP, adenoviral gene expression was evidenced by the observation of shiny GFP deposits along the vessel walls under fluorescence microscopy throughout the whole cremaster flap 2 days after transfection. At day 3 there was no evidence of any differences in capillary density and permeability index (PI). At day 7, the functional capillary density was significantly higher in the Ad-Ang-1-treated group compared with the control and the Ad-GFP groups (10/hpf +/- 2 vs. 7/hpf +/- 0.5, p = 0.006; 5/hpf +/- 1.6, p = 0.0001). The PI in the Ad-Ang-1-treated group was significantly lower compared with the Ad-GFP-treated group (1.1/hpf +/- 0.1% vs. 1.4/hpf +/- 0.1%, p = 0.0005). At 14 days, the number of the flowing capillaries was significantly higher in the Ad-Ang-1-treated group compared with the control and the Ad-GFP-treated groups (13/hpf +/- 1.7 vs. 9/hpf +/- 2 and 6/hpf +/- 1.3, p = 0.0001). The microvascular PI was significantly lower in the Ad-Ang-1-treated group compared with the Ad-GFP-treated group (1.3/hpf +/- 0.2% vs. 1.8/hpf +/- 0.5%, p = 0.004). Histologically, the cremaster flaps revealed focal and mild inflammation regardless of the treatment and time point of evaluation. There was evidence of vasculitis in muscles pretreated with Ad-GFP and Ad-Ang-1. In summary, in the Ad-Ang-1-treated cremaster flaps, functional capillary density increased from 46% at day 7 to 98% at day 14 when compared with the control group (p < 0.0001). In conclusion, in this experimental muscle flap model, Ad-Ang-1 treatment proved to be a successful method of angiogenic therapy, providing a long-lasting angiogenic effect over a period of 14 days. The increased capillary perfusion accompanied by the formation of more stable and mature vessels resistant to fluorescein isothiocyanate-conjugated albumin leakage may serve as in vivo evidence that Ang-1 therapy improves skeletal muscle flap hemodynamics. These exciting findings raise the possibility that Ang-1 may have implications for therapeutic angiogenesis. To the authors' knowledge, their study demonstrates for the first time the feasibility of intravascular gene therapy using a virus vector in an attempt to enhance muscle flap hemodynamics." @default.
• W1971114015 created "2016-06-24" @default.
• W1971114015 creator A5040978847 @default.
• W1971114015 creator A5058048785 @default.
• W1971114015 creator A5060595502 @default.
• W1971114015 creator A5068338476 @default.
• W1971114015 creator A5073712650 @default.
• W1971114015 date "2002-04-01" @default.
• W1971114015 modified "2023-10-02" @default.
• W1971114015 title "Enhancement of Muscle Flap Hemodynamics by Angiopoietin-1" @default.
• W1971114015 cites W1598900543 @default.
• W1971114015 cites W1679229092 @default.
• W1971114015 cites W1762724222 @default.
• W1971114015 cites W1970614272 @default.
• W1971114015 cites W1971957168 @default.
• W1971114015 cites W1973515582 @default.
• W1971114015 cites W1974045062 @default.
• W1971114015 cites W1988010872 @default.
• W1971114015 cites W1990187729 @default.
• W1971114015 cites W1992638959 @default.
• W1971114015 cites W1996430165 @default.
• W1971114015 cites W2000537146 @default.
• W1971114015 cites W2002396327 @default.
• W1971114015 cites W2031756364 @default.
• W1971114015 cites W2035527077 @default.
• W1971114015 cites W2042427065 @default.
• W1971114015 cites W2052612816 @default.
• W1971114015 cites W2056956145 @default.
• W1971114015 cites W2066888615 @default.
• W1971114015 cites W2066993893 @default.
• W1971114015 cites W2074388861 @default.
• W1971114015 cites W2078348571 @default.
• W1971114015 cites W2084452119 @default.
• W1971114015 cites W2119841264 @default.
• W1971114015 cites W2121155498 @default.
• W1971114015 cites W2136480937 @default.
• W1971114015 cites W2140459348 @default.
• W1971114015 cites W2155783433 @default.
• W1971114015 cites W280737749 @default.
• W1971114015 doi "https://doi.org/10.1097/00000637-200204000-00011" @default.
• W1971114015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12068223" @default.
• W1971114015 hasPublicationYear "2002" @default.
• W1971114015 type Work @default.
• W1971114015 sameAs 1971114015 @default.
• W1971114015 citedByCount "18" @default.
• W1971114015 countsByYear W19711140152013 @default.
• W1971114015 countsByYear W19711140152016 @default.
• W1971114015 countsByYear W19711140152018 @default.
• W1971114015 crossrefType "journal-article" @default.
• W1971114015 hasAuthorship W1971114015A5040978847 @default.
• W1971114015 hasAuthorship W1971114015A5058048785 @default.
• W1971114015 hasAuthorship W1971114015A5060595502 @default.
• W1971114015 hasAuthorship W1971114015A5068338476 @default.
• W1971114015 hasAuthorship W1971114015A5073712650 @default.
• W1971114015 hasConcept C105702510 @default.
• W1971114015 hasConcept C123012128 @default.
• W1971114015 hasConcept C126322002 @default.
• W1971114015 hasConcept C12722491 @default.
• W1971114015 hasConcept C141071460 @default.
• W1971114015 hasConcept C158846371 @default.
• W1971114015 hasConcept C167734588 @default.
• W1971114015 hasConcept C178853913 @default.
• W1971114015 hasConcept C202751555 @default.
• W1971114015 hasConcept C2776354463 @default.
• W1971114015 hasConcept C2776820930 @default.
• W1971114015 hasConcept C2777025900 @default.
• W1971114015 hasConcept C2779094623 @default.
• W1971114015 hasConcept C2780394083 @default.
• W1971114015 hasConcept C2859252 @default.
• W1971114015 hasConcept C55493867 @default.
• W1971114015 hasConcept C71924100 @default.
• W1971114015 hasConcept C85219853 @default.
• W1971114015 hasConcept C86803240 @default.
• W1971114015 hasConceptScore W1971114015C105702510 @default.
• W1971114015 hasConceptScore W1971114015C123012128 @default.
• W1971114015 hasConceptScore W1971114015C126322002 @default.
• W1971114015 hasConceptScore W1971114015C12722491 @default.
• W1971114015 hasConceptScore W1971114015C141071460 @default.
• W1971114015 hasConceptScore W1971114015C158846371 @default.
• W1971114015 hasConceptScore W1971114015C167734588 @default.
• W1971114015 hasConceptScore W1971114015C178853913 @default.
• W1971114015 hasConceptScore W1971114015C202751555 @default.
• W1971114015 hasConceptScore W1971114015C2776354463 @default.
• W1971114015 hasConceptScore W1971114015C2776820930 @default.
• W1971114015 hasConceptScore W1971114015C2777025900 @default.
• W1971114015 hasConceptScore W1971114015C2779094623 @default.
• W1971114015 hasConceptScore W1971114015C2780394083 @default.
• W1971114015 hasConceptScore W1971114015C2859252 @default.
• W1971114015 hasConceptScore W1971114015C55493867 @default.
• W1971114015 hasConceptScore W1971114015C71924100 @default.
• W1971114015 hasConceptScore W1971114015C85219853 @default.
• W1971114015 hasConceptScore W1971114015C86803240 @default.
• W1971114015 hasIssue "4" @default.
• W1971114015 hasLocation W19711140151 @default.
• W1971114015 hasLocation W19711140152 @default.
• W1971114015 hasOpenAccess W1971114015 @default.
• W1971114015 hasPrimaryLocation W19711140151 @default.
• W1971114015 hasRelatedWork W1852122062 @default.

• next